BTK Inhibitors for CLL Lower Response to Some Vaccines
A team of investigators conducted a phase 2 trial to assess outcomes of hepatitis C virus and varicella zoster vaccination in patients with treatment-naive CLL or those on BTK inhibitor therapy.
Chronic Lymphocytic Leukemia
The Role of Early Intervention in the Treatment of Early-Stage CLL
There is a need for further investigation of early intervention options for patients with early-stage CLL.
Lenalidomide Maintenance Therapy Linked With B-Cell Acute Lymphoblastic Leukemia in Patients With Chronic Lymphocytic Leukemia
Researchers sought to describe a potential link between treatment with lenalidomide and development of B-cell ALL in patients with CLL.
Clinical Trial: Investigational BTK Inhibitor Undergoes Investigation in CLL, B-Cell Lymphoma
Investigators will study the pharmacokinetic and pharmacodynamic profile of TG-1701, an irreversible Bruton tyrosine kinase (BTK) inhibitor, in the phase 1 setting.
Leukemia: Fact Sheet for Patients
Almost everyone has heard of leukemia, but most people do not have a good understanding of this complex disease. How can healthcare providers explain the basics of leukemia to their patients?
Idelalisib Does Not Increase Risk for Bleeding in Patients With CLL, Indolent NHL Receiving Anticoagulation/Antiplatelet Therapy
This post-hoc analysis assessed the incidence and characteristics of bleeding-related adverse events in patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma enrolled in the idelalisib registration trials.
Prognostic Biomarker Testing in CLL/SLL Remains Low
Clinicians are not following guideline recommendations, as prognostic biomarker testing for CLL/SLL remains low and affects treatment selection.
Liso-Cel Plus Ibrutinib Demonstrated Efficacy in R/R CLL/SLL
A phase 1 trial demonstrated antitumor activity of liso-cel plus ibrutinib with low rates of grade 3 or higher CRS and neurotoxicity among heavily pretreated patients with CLL/SLL.
Fixed Duration Ibrutinib-Venetoclax for CLL Resulted in High Rate of Undetectable MRD
Confirmed undetectable MRD after 12 cycles may result in treatment discontinuation.
Sustained CLL Response Seen With Ibrutinib Plus Venetoclax After MRD Negativity
Even patients who did not achieve MRD negativity at 1 year had stable or decreasing disease levels.
-
Loading...
-
Loading...
Next post in ASH 2020
